and cancer: new technologies offer therapeutic opportunities. Bioessays. 2010, 32:589�?8. 107. RAD001 Everolimus Tse E, Lobato MN, Forster A, Tanaka T, Chung GT, Rabbitts TH. Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J Mol Biol. 2002, 317:85�?4. 108. Wojcik J, Hantschel O, Grebien F, et al. A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol. 2010, 17:519�?7. 109. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011, 29:591�?. 110. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009, 458:776�?. 111.
Irvine DA, Zhang B, Allan EK, et al. Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid flt-3 inhibitor drug Leukemia Stem and Progenitor Cells. American Society of Hematology Annual Meeting. 2009 Poster #1428. 112. Sheridan C. Genentech obtains proof of concept for hedgehog inhibition. Nat Biotech. 2009, 27:968�?. 113. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007, 12:528�?1. 114. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010, 463:676�?0. 115. Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
Mol Cancer Ther. 2008, 7:48�?8. 116. Gregory MA, Phang TL, Neviani P, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010, 18:74�?7. 117. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009, 119:1109�?3. 118. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001, 61:6846�?0. 119. Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.
Nat Genet. 2009, 41:783�?2. Woessner et al. Page 15 Cancer J. Author manuscript, available in PMC 2012 May 1. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript 120. Mancini M, Corradi V, Petta S, Martinelli G, Barbieri E, Santucci MA. mTOR inhibitor RAD001 enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res. 2010, 34:641�?. 121. Warsch W, Kollmann K, Eckelhart E, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011, 117:3409�?0. 122. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007, 7:441�?3. 123. Nelson EA, Walker SR, Weisberg E, et al.
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011, 117:3421�?. 124. Melo, JV., Goldman, JM., Deininger, M. Myeloproliferative Disorders. Springer, Berlin Heidelberg: 2007. Signal Transduction Inhibitors in Chronic Myeloid Leukemia, p. 75-102. Table References 1. Iacob RE, Zhang J, Gray NS, Engen JR. Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One. 2011, 6:e15929. 2. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL override